Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174453 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
A Phase 3 study of Solid Tumor Malignancies, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 1
- Study location
NCT07174453 is a Phase 3 study of Solid Tumor Malignancies that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 192 participants, roughly in line with the 178-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07174453, a Phase 3 study of Solid Tumor Malignancies, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 3/4 open label, randomized two cohort study (2 arms in each cohort). It is hypothesized that for people with a histologically or cytologically confirmed diagnosis of malignancy, the higher dose immunotherapy (every 6 weeks Pembrolizumab 400mg dose and every 4 weeks Nivolumab 480mg dose) has more immune-related adverse events irAEs compared to lower dose (every 3 weeks Pembrolizumab 200mg dose and every 2 weeks Nivolumab 240mg dose).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
Study Locations (1)
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2029-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174453
The ClinicalTrials.gov registry entry for NCT07174453 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 178-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07174453 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT07174453 about?
NCT07174453 is a clinical study titled "Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies". Phase 3/4 open label, randomized two cohort study (2 arms in each cohort). It is hypothesized that for people with a histologically or cytologically confirmed diagnosis of malignancy, the higher dose immunotherapy (every 6 weeks Pembrolizumab 400mg dose and every 4 weeks Nivolumab 480mg dose) has m...
What is the current status of trial NCT07174453?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2025-10-07. Estimated completion is 2029-10-01.
What conditions does trial NCT07174453 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies.
What interventions are being tested in trial NCT07174453?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT07174453?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174453 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.